Stargardt Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Macular dystrophy comprises a set of hereditary disorders characterized by retinal irregularities located between the temporal vascular arcades. Stargardt disease (STGD1) is the most frequent cause of juvenile macular dystrophy among these. It follows an autosomal recessive inheritance pattern, primarily linked to mutations in the adenosine triphosphate binding cassette transporter 4 (ABCR 4) gene. This genetic anomaly results in the accumulation of lipofuscin, a metabolic waste product, within the retina. The disease exhibits substantial heterogeneity in clinical manifestations, including variations in age of onset and progression rate. Patients experience a gradual decline in vision, usually commencing in their first or second decades of life. Presently, no approved treatments prevent or reverse visual deterioration in individuals with STGD1. Medical advice for patients centers on photoprotection to slow the disease's progression and provide low-vision aids for those with compromised visual fields. As the disease advances, many patients eventually reach legal blindness due to the loss of central vision, although peripheral vision often remains intact. The prognosis is highly variable and heavily contingent on the age of disease onset. Those with early onset typically face unfavorable outcomes, with a rapid decline in visual acuity, progressive retinal degeneration, and the potential development of profound chorioretinal atrophy. Consequently, individuals with this phenotype experience a severe form of the disease with a grim prognosis. In contrast, rapid-onset chorioretinopathy (ROC) represents a distinct sub-phenotype marked by swift disease progression. On the other hand, patients with late-onset disease typically maintain good visual acuity even into their later years. Fortunately, this condition does not significantly affect general health or life expectancy.

 

Thelansis’s “Stargardt Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stargardt Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Stargardt Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Stargardt Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Stargardt Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Stargardt Disease, Stargardt Disease market outlook, Stargardt Disease competitive landscape, Stargardt Disease market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)